You are viewing AANS Neurosurgeon Volume 27, Number 4, 2018. View our current issue, Volume 28, Number 2, 2019

AANS Neurosurgeon | Volume 27, Number 4, 2018


Interim Results from Clinical Trial of Immunotherapy for Glioblastoma Show Significant Clinical Benefit

Print Friendly, PDF & Email

Team from Roswell Park, MimiVax LLC and Cleveland Clinic to report findings on SurVaxM at ASCO Annual Meeting


The research team behind an emerging immunotherapy for cancer will present interim findings from an ongoing clinical study in patients with brain cancer at a major research meeting next month. Collaborators from organizations including Roswell Park Comprehensive Cancer Center, the Cleveland Clinic and MimiVax LLC will share data from their phase II study of SurVaxM as part of a combination treatment for patients with glioblastoma at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. These results show that the therapy appears to be safe, effective and worthy of further evaluation.

Glioblastoma is the most common and aggressive form of primary brain cancer in adults. With standard therapy — surgery followed by chemoradiation and then adjuvant chemotherapy — the median overall survival is 15 months, with only 3-5% of patients living 5 years or more.

Click here to read more.


NeuroSafe 2019 Symposium
Aug. 8-9, 2019; Minneapolis

SNSA Congress 2019
Aug. 8-11, 2019; Cape Town, South Africa

2019 Managing Coding and Reimbursement Challenges
Aug. 22-24, 2019; Rosemont, Ill.

Comments are closed.